Tongyoung Lee

CEO
StemCyte International, Ltd.
​
​`

Dr. Lee is CEO of StemCyte Inc. StemCyte's rich history started with a mission of dedication to helping the world's physicians save more lives by providing high quality, safe and effective stem cell transplantation and therapy to all patients in need. Located in the US, India, and Taiwan, StemCyte has supplied over 2300 cord blood units for a variety of life-threatening diseases to over 300 leading worldwide transplant centers in past decades. StemCyte is actively involved in the development of cell therapies. StemCyte was chosen by the US Department of Health and Human Services to help establish a public National Cord Blood Inventory.
Since the year of 2021, Dr. Lee joined StemCyte, company has several obviously progress including one US FDA BLA has approved, two UD FDA phase II trials are ongoing, and one TFDA phase I trial is finished. Dr. Lee’s experiences are in the multiple status conversions of scientist, professional manager, entrepreneur, and business operator.
He was founder of Celtec Inc. and Protect Inc. that were focus on novel cellular immunotherapies and immune-checkpoint relative drug development for pet application separately. He was also the initial development team member of FB825 at Oneness Biotech, which is an mAb drug for several diseases’ application. This project was out-licensing to LEO pharma with USD 530 million on 2020. Dr. Lee’s Post-Doc training was work with late Dr. Judah Folkman at Harvard Medical School for many years. Judah Folkman, M.D. (1933-2008), known as the father of angiogenesis research. Three angiogenesis inhibitors, bevacizumab (Avastin), ranibizumab (Lucentis) and ranibizumab (Eylea) were the first to be approved by the U.S. Food and Drug Administration and are now playing a major role in treatment.

Speech title & Synopsis

Company Profile

REGENECYTE, HPC (Hematopoietic Progenitor Cell), Cord Blood, is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoietic progenitor cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment.
To date, only eight non-profit organizations with public cord blood banks have obtained FDA BLA status, and StemCyte is the first private organization to receive this license for its cell product "RegeneCyte. Our mission is to further develop our cord blood banking capabilities and strive to deliver life-saving therapies to patients suffering from degenerative and other life-threatening diseases.